Biora Therapeutics Lands in the Middle of Healthcare Sector: InvestorsObserver
June 24, 2023
🌥️Trending News
Biora Therapeutics ($NASDAQ:BIOR) Inc. is making a name for itself in the healthcare sector. The company focuses on developing and supplying advanced biotherapeutic products and services with the goal of improving patient care and outcomes. Biora Therapeutics is currently focusing on the development and commercialization of innovative biotherapeutic products, including Plasma-Derived Biotherapies (PDBs), that provide cost effective and efficient treatment options for patients in need. Biora Therapeutics has a strong history of success in the healthcare sector, as it has established itself as a reliable provider of biotherapeutic products.
Furthermore, the company has developed strategic partnerships with leading healthcare organizations in order to better serve patients. With its commitment to patient care and innovative products, Biora Therapeutics stands out from other players in the healthcare sector and is a great choice for investors looking for potential returns.
Share Price
On Thursday, BIORA THERAPEUTICS stock opened at $4.9 and closed at $4.5, representing a drop of 5.1% from its last closing price of $4.7. With this sudden fall in the share price, BIORA THERAPEUTICS landed in the middle of the healthcare sector with investors keeping an eye on the company’s performance going forward. This decline could be attributed to the fact that the company has not been able to live up to its promise and investors confidence has been lost over time.
However, with the recent decline in share price, it is yet to be seen as to whether the company can regain investors’ trust or not. Moreover, given the competitive market landscape, BIORA THERAPEUTICS needs to ensure that it remains competitive and has a sustainable business model that can attract new investors and retain existing ones. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biora Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.2 | -41.79 | -32280.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biora Therapeutics. More…
| Operations | Investing | Financing |
| -52.56 | -0.46 | 16.25 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biora Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 53.24 | 158.24 | -8.85 |
Key Ratios Snapshot
Some of the financial key ratios for Biora Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -87.9% | – | -20645.5% |
| FCF Margin | ROE | ROA |
| -26513.0% | 24.9% | -48.5% |
Analysis
At GoodWhale, we believe in providing investors with the most comprehensive analysis of BIORA THERAPEUTICS‘ fundamentals available. After an extensive review of the company’s financial and business aspects, we have assigned a high risk rating to BIORA THERAPEUTICS. Our review identified five distinct risk warnings in their income sheet, balance sheet, cashflow statement, non financial and financial journals. If you’re interested in delving deeper, be sure to register on GoodWhale.com and check out our detailed analysis for yourself. More…
Peers
The competition in the field of cancer therapeutics is heating up, with Biora Therapeutics Inc taking on NuCana PLC, GT Biopharma Inc, and CytomX Therapeutics Inc. While each company has its own unique approach to cancer treatment, they are all striving to be the best in the field. May the best company win!
– NuCana PLC ($NASDAQ:NCNA)
NuCana PLC is a pharmaceutical company that focuses on the development and commercialization of cancer treatments. The company has a market capitalization of $52.2 million and a return on equity of -44.76%. NuCana PLC’s products are designed to improve the treatment of cancer by targeting the disease at the cellular level. The company’s products are in various stages of development, including clinical trials.
– GT Biopharma Inc ($NASDAQ:GTBP)
ACGT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapies for the treatment of cancer. The company’s lead product candidates are ACGT087, a monoclonal antibody targeting CD73, and ACGT141, a monoclonal antibody targeting CTLA-4. ACGT Biopharma Inc is headquartered in San Diego, California.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company developing a novel class of investigational antibody therapeutics based on its Probody platform. The Probody platform is designed to improve the therapeutic index of antibodies by targeting them to cancer cells while limiting exposure to healthy tissues. CytomX’s lead product candidate, CX-072, is an anti-CD166 Probody therapeutic antibody in Phase 1 clinical testing for the treatment of solid tumors.
Summary
Biora Therapeutics Inc is a healthcare company that is currently ranked in the middle of the sector according to InvestorsObserver. Recently, the stock price has decreased, making it an attractive opportunity for investors who are looking to capitalize on a potential bargain. This could be a result of recent market volatility or changes in the company’s performance.
Analysts will need to review company financials and news reports to determine the cause of this stock movement before making any investment decisions. It is important to note that investing in Biora Therapeutics comes with its own risk factors, and investors should consider these when making any decisions.
